Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Bupropion and varenicline are indicated for smoking cessation. The objectives of this study
are two-fold: (1) to explore the logistic feasibility of distributing bupropion and
varenicline free of charge to treatment-seeking smokers in the province of Ontario, Canada
and (2) to evaluate the real-world effectiveness of bupropion and varenicline treatment in
Ontario compared to a no-drug comparison group. In an open label study, Ontario smokers who
smoke 10 or more cigarettes per day and intend to quit smoking in the next 30 days, will
enroll via the study website, visit their physician to receive a prescription for bupropion
or varenicline for 12 weeks or neither if they so choose, forming the no-drug comparison
group. All participants will receive weekly motivational emails for 12 weeks. Abstinence
measures will be taken at 4, 8 and 12 weeks and at 6 and 12 months. The proportion of
eligible participants who were able to confirm an appointment with a physician to receive the
prescription will be also measured.
Phase:
Phase 4
Details
Lead Sponsor:
Centre for Addiction and Mental Health
Collaborators:
Ontario Ministry of Health and Long Term Care Ontario Ministry of Health Promotion & Sport